Voyager Therapeutics, Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. This is an annual report, not a standalone fourth-quarter report. Voyager is a clinical-stage AAV gene-therapy company focused on severe neurological diseases; it had no approved products and no product-sales revenue.
Financial results and liquidity
| Metric | FY2020 | FY2019 |
|---|---|---|
| Collaboration revenue | $171.1 million | $104.4 million |
| Research and development expense | $108.8 million | $119.7 million |
| General and administrative expense | $35.0 million | $36.3 million |
| Operating income (loss) | $27.4 million | $(51.7) million |
| Net income (loss) | $36.7 million | $(43.6) million |
| Net cash used in operating activities | $(96.7) million | $48.7 million provided |
| Cash, cash equivalents and marketable debt securities | $174.8 million | — |
FY2020 collaboration revenue comprised $50.8 million from the AbbVie tau collaboration, $63.7 million from the AbbVie alpha-synuclein collaboration, and $56.7 million from Neurocrine. The AbbVie amounts included $105.2 million of deferred revenue recognized after the collaborations terminated and Voyager’s related obligations were completed. Accordingly, reported earnings and operating income were materially affected by collaboration accounting and do not indicate product-sales profitability. Interest income was $1.7 million; other income was $7.7 million, primarily related to gains on Voyager’s ClearPoint Neuro stock and warrants.
At year-end, total assets were $261.6 million, total liabilities $107.3 million, and stockholders’ equity $154.3 million. The filing reports $47.6 million of operating lease liabilities and future minimum lease payments of $63.6 million. It does not present conventional borrowings as a material debt balance. No meaningful commercial-product margin was reported because the company had no product sales.
Material changes versus prior periods
- Revenue rose $66.7 million from 2019, primarily because termination of both AbbVie collaborations accelerated recognition of remaining deferred revenue.
- Voyager recorded net income of $36.7 million versus a $43.6 million net loss in 2019; management attributed the 2020 result primarily to AbbVie termination-related revenue recognition.
- Operating cash flow shifted from $48.7 million provided in 2019 to $96.7 million used in 2020, largely reflecting the $150.7 million decrease in deferred revenue in the cash-flow reconciliation.
- R&D expense declined $11.0 million, mainly from lower external program costs, partly offset by higher employee and facility costs.
- Cash, cash equivalents and marketable debt securities were $174.8 million at year-end. Management expected these resources, together with anticipated Neurocrine reimbursements, to fund planned operations into mid-2022.
Outlook, risks and unusual items
- Voyager expects continued operating losses and increased development spending; it anticipates needing additional financing or business-development transactions and does not expect product-sales revenue in the near term.
- The FDA placed the VY-HTT01 Huntington’s disease IND on clinical hold in October 2020 for additional chemistry, manufacturing and controls information. Voyager expected to respond in the first half of 2021; trial initiation depended on resolving the hold and IND clearance.
- The FDA placed the RESTORE-1 Phase 2 VY-AADC Parkinson’s trial on clinical hold in December 2020 after MRI abnormalities were identified in some participants. The DSMB described their clinical significance as uncertain and requested more information. FDA requests included an assessment of potential product contribution, a mitigation plan, and support for a favorable benefit-risk profile.
- In February 2021, after the reporting year, Neurocrine notified Voyager that it would terminate the VY-AADC collaboration effective August 2, 2021. Voyager expected to regain worldwide rights then, but Neurocrine remained trial sponsor and IND holder while the hold-related information was being addressed. The termination will end Neurocrine reimbursement for VY-AADC work after the effective date.
- Neurocrine’s other programs, including Friedreich’s ataxia and discovery programs, remained under the collaboration. Continued reimbursement and program budgets depend on progress and agreed plans.
- COVID-19 disrupted or slowed clinical-site activity and reduced on-site laboratory work; the company delayed or discontinued some non-critical preclinical experiments. The extent of future effects was uncertain.
- A putative securities class action was filed in January 2021 concerning alleged misstatements or omissions about the Huntington’s program and VY-HTT01 IND. Voyager denied wrongdoing and stated it intended to defend the case. No material litigation contingency was recorded at December 31, 2020.
- The company reported no off-balance-sheet arrangements. Management and the auditor concluded internal control over financial reporting was effective; the financial-statement audit opinion was unqualified.
Key facts for investors to verify
- How much of 2020’s $171.1 million revenue and $36.7 million net income reflected one-time recognition of deferred collaboration revenue, versus recurring reimbursed research activity.
- The timing and outcome of FDA responses and any restart decisions for the VY-HTT01 IND and RESTORE-1 clinical hold, including the significance and cause of the MRI abnormalities.
- The operational and financial effect of Neurocrine’s VY-AADC termination, including future reimbursement, program costs, and the practical path to regain and advance the program.
- Whether the stated mid-2022 cash runway remains achievable after changes in collaboration funding, development plans, and spending.
- Future financing needs and potential dilution, as well as the status and potential impact of the securities class action.